Table 1: Definitions Used in the AJCC Lung Cancer Staging System
Table 2: AJCC Staging of NSCLC
Table 3: Symptoms of NSCLC
Table 4: Prognostic Factors for NSCLC
Table 5: Prognosis for NSCLC Based on Initial Staging
Table 6: Prevalence of Brain and Bone Metastases in NSCLC
Table 7: Biomarker Testing Rates in Nonsquamous NSCLC
Table 8: Biomarker Testing Rates in Squamous NSCLC
Table 9: Treatment Guidelines for NSCLC
Table 10: Most Prescribed Drugs for NSCLC by Class in the 8MM, 2015–2025
Table 11: Country Profile – China
Table 12: Leading Treatments for NSCLC, 2016
Table 13: Marketed EGFR TKIs in NSCLC
Table 14: Product Profile – Tarceva
Table 15: Efficacy of Tarceva in First-Line Therapy, EGFR-mutant NSCLC
Table 16: Efficacy of Tarceva in Maintenance Therapy in NSCLC
Table 17: Efficacy of Tarceva in Second- and Third-Line Therapy in NSCLC
Table 18: Safety of Tarceva
Table 19: Tarceva SWOT Analysis, 2016
Table 20: Product Profile – Iressa
Table 21: Efficacy of Iressa in First-Line, EGFR-Mutant NSCLC (Study 1)
Table 22: Efficacy of Iressa in First-Line, EGFR-Mutant ADC NSCLC (Study 2)
Table 23: Safety of Iressa
Table 24: Iressa SWOT Analysis, 2016
Table 25: Product Profile – Gilotrif
Table 26: Efficacy of Gilotrif in First-Line, EGFR-Mutant ADC
Table 27: Efficacy of Gilotrif in First-Line, EGFR-Mutant ADC
Table 28: Efficacy of Gilotrif in Second-Line, EGFR-Wildtype, EGFR TKI-Naïve, Squamous NSCLC
Table 29: Efficacy of Gilotrif in Fourth-Line, EGFR-Mutant NSCLC
Table 30: Safety of Gilotrif
Table 31: Gilotrif SWOT Analysis, 2016
Table 32: Product Profile – Tagrisso
Table 33: Efficacy of Tagrisso in Second-Line, EGFR-Mutant NSCLC
Table 34: Safety of Tagrisso
Table 35: Tagrisso SWOT Analysis, 2016
Table 36: Product Profile – Portrazza
Table 37: Efficacy of Portrazza in First-Line, Squamous NSCLC
Table 38: Safety of Portrazza
Table 39: Portrazza SWOT Analysis, 2016
Table 40: Efficacy of Conmana in 2L Advanced NSCLC
Table 41: Efficacy of Conmana in 1L EGFR-mutant NSCLC
Table 42: Safety of Conmana
Table 43: Conmana SWOT Analysis, 2016
Table 44: Marketed ALK TKIs in NSCLC
Table 45: Product Profile – Xalkori
Table 46: Efficacy of Xalkori in Treatment-Naïve ALK+ Metastatic NSCLC
Table 47: Efficacy of Xalkori in Previously Treated ALK+ Metastatic NSCLC
Table 48: Safety of Xalkori in Treatment-Naïve, ALK+ Metastatic NSCLC
Table 49: Safety of Xalkori in Previously Treated, Metastatic NSCLC
Table 50: Xalkori SWOT Analysis, 2016
Table 51: Product Profile – Zykadia
Table 52: Efficacy of Zykadia
Table 53: Safety of Zykadia
Table 54: Zykadia SWOT Analysis, 2016
Table 55: Product Profile – Alecensa
Table 56: Efficacy of Alecensa
Table 57: Efficacy of Alecensa in NSCLC patients with CNS lesions
Table 58: Safety of Alecensa
Table 59: Alecensa SWOT Analysis, 2016
Table 60: Marketed PD-1/PD-L1 ICIs in NSCLC
Table 61: Product Profile – Opdivo
Table 62: Efficacy of Opdivo in Metastatic Squamous NSCLC
Table 63: Efficacy of Opdivo in Metastatic Nonsquamous NSCLC
Table 64: Safety of Opdivo
Table 65: Opdivo SWOT Analysis, 2016
Table 66: Product Profile – Keytruda
Table 67: Efficacy of Keytruda
Table 68: Safety of Keytruda
Table 69: Keytruda SWOT Analysis, 2016
Table 70: Product Profile – Tecentriq (atezolizumab)
Table 71: Patient Demographics in the Phase II POPLAR Trial (NCT01903993)
Table 72: Efficacy of Tecentriq in the Phase II POPLAR Trial (NCT01903993)
Table 73: Efficacy of Tecentriq in the Phase III OAK Trial (NCT02008227)
Table 74: Patient Demographics in the Phase II FIR Trial (NCT01846416)
Table 75: Efficacy of Tecentriq in the Phase II FIR Trial (NCT01846416)
Table 76: Efficacy of Tecentriq in the Phase II BIRCH Trial (NCT02031458)
Table 77: Safety of Tecentriq in the Phase II POPLAR Trial (NCT01903993)
Table 78: Safety of Tecentriq in the Phase II FIR Trial (NCT01846416)
Table 79: Tecentriq SWOT Analysis, 2016
Table 80: Product Profile – Avastin
Table 81: Efficacy of Avastin in Nonsquamous NSCLC
Table 82: Safety of Avastin
Table 83: Avastin SWOT Analysis, 2016
Table 84: Product Profile – Cyramza
Table 85: Efficacy of Cyramza
Table 86: Safety of Cyramza
Table 87: Cyramza SWOT Analysis, 2016
Table 88: Product Profile – Vargatef
Table 89: Efficacy of Vargatef in ADC NSCLC
Table 90: Safety of Vargatef in ADC NSCLC
Table 91: Vargatef SWOT Analysis, 2016
Table 92: Summary of Chemotherapies, 2015
Table 93: Unmet Need and Opportunity in NSCLC
Table 94: Product Profile – Yervoy (ipilimumab)
Table 95: Demographics in the Phase II NCT00527735 Trial
Table 96: Efficacy of Yervoy + Carboplatin + Paclitaxel in Advanced NSCLC (NCT00527735)
Table 97: Demographics in the Phase I CheckMate 012 Trial (NCT01454102)
Table 98: Efficacy of the Opdivo + Yervoy Combination in the CheckMate 012 Trial (NCT01454102)
Table 99: Safety of Yervoy (ipilimumab) + Carboplatin + Paclitaxel in Advanced NSCLC (NCT00527735)
Table 100: Safety of the Opdivo + Yervoy Combination in the CheckMate 012 Trial (NCT01454102)
Table 101: Yervoy SWOT Analysis, 2016
Table 102: Product Profile – Avelumab (MSB-0010718C)
Table 103: Patient Demographics in the Phase Ib Dose-Expansion Study (NCT01772004)
Table 104: Efficacy of Avelumab in the Phase Ib Dose-Expansion Study (NCT01772004)
Table 105: Efficacy of Avelumab in PD-L1-Positive and -Negative NSCLC
Table 106: Demographics in the Treatment-Naïve NSCLC Cohort in the Phase I Trial (NCT01772004)
Table 107: Efficacy of Avelumab in Treatment-Naïve NSCLC
Table 108: Unconfirmed ORR According to PD-L1 Expression in Treatment-Naïve NSCLC
Table 109: Safety of Avelumab in the Phase Ib Dose-Expansion Study (NCT01772004)
Table 110: Safety of Avelumab in Treatment-Naïve NSCLC (NCT01772004)
Table 111: Avelumab SWOT Analysis, 2016
Table 112: Product Profile – Durvalumab (MEDI4736)
Table 113: Patient Demographics and Disease Characteristics in the Phase I/II NCT01693562 Trial
Table 114: Efficacy of Durvalumab in the Phase I/II NCT01693562 Trial
Table 115: Baseline Characteristics of Patients With Treatment-Naïve NSCLC in the Phase I/II
Table 116: Efficacy of Durvalumab in Treatment-Naïve NSCLC
Table 117: Patient Demographics and Disease Characteristics in the Phase Ib NCT02000947 Trial
Table 118: Efficacy of Durvalumab + Tremelimumab in the Phase Ib NCT02000947 Trial
Table 119: Safety of Durvalumab in the Phase I/II Trial (NCT01693562)
Table 120: Safety of Durvalumab in Treatment-Naïve NSCLC
Table 121: Safety of Durvalumab + Tremelimumab in the Phase Ib NCT02000947 Trial
Table 122: Durvalumab SWOT Analysis, 2016
Table 123: Product Profile – Naquotinib Mesylate (ASP8273)
Table 124: Patient Demographics in the Phase I/II NCT02192697 and Phase I NCT02113813 Trials
Table 125: Efficacy of Naquotinib in EGFR-Mutant NSCLC in Japanese and US Patients
Table 126: Safety of Naquotinib in EGFR-Mutant NSCLC in Japanese and US Patients
Table 127: Naquotinib SWOT Analysis, 2016
Table 128: Product Profile – Olmutinib (BI 1482694; HM61713)
Table 129: Demographics in the Phase I/II NCT01588145 Trial
Table 130: Efficacy of Olmutinib in the Phase II Portion of the NCT01588145 Trial
Table 131: Safety Profile of Olmutinib in the Phase II Portion of the NCT01588145 Trial
Table 132: Olmutinib SWOT Analysis, 2016
Table 133: Product Profile – Dacomitinib
Table 134: Demographics in the Phase II NCT00818441 Trial
Table 135: Efficacy of Dacomitinib in the Phase II NCT00818441 Trial
Table 136: Safety of Dacomitinib in Phase II NCT00818441 Trial
Table 137: Dacomitinib SWOT Analysis, 2016
Table 138: Product Profile – Ensartinib
Table 139: Baseline Patient Characteristics in the Phase I/II eXalt2 Trial (NCT0162534)
Table 140: Efficacy of Ensartinib in the Phase I/II eXalt2 Trial (NCT0162534)
Table 141: Baseline Patient Characteristics in the Expansion Cohort of the Phase I/II eXalt2 Trial
Table 142: Efficacy of Ensartinib in the Expansion Phase of the eXalt2 Trial (NCT0162534)
Table 143: Safety of Ensartinib in the Phase I/II eXalt2 Trial (NCT0162534)
Table 144: Ensartinib SWOT Analysis, 2016
Table 145: Product Profile – Brigatinib
Table 146: Baseline Patient Characteristics in the Phase II ALTA Trial (NCT02094573)
Table 147: Efficacy of Brigatinib in the Phase II ALTA Trial (NCT02094573)
Table 148: Efficacy of Brigatinib in ALK+ NSCLC with Intracranial CNS Metastases
Table 149: Safety of Brigatinib in the Phase II ALTA Trial (NCT02094573)
Table 150: Brigatinib SWOT Analysis, 2016
Table 151: Product Profile – CimaVax-EGF
Table 152: Demographics in the Phase III trial of the CimaVax-EGF in Cuba
Table 153: Efficacy of the CimaVax-EGF in the Phase III trial in Cuba
Table 154: Safety of the CimaVax-EGF in the Phase III Trial in Cuba
Table 155: CimaVax-EGF SWOT Analysis, 2016
Table 156: Product Profile – Tedopi
Table 157: Demographics in the Phase II Trial of Tedopi in Advanced NSCLC
Table 158: Efficacy of Tedopi in Advanced NSCLC
Table 159: Tedopi SWOT Analysis, 2016
Table 160: Product Profile – Anlotinib
Table 161: Efficacy of Anlotinib in Pretreated NSCLC in the Phase II ALTER0302 Trial
Table 162: Anlotinib SWOT Analysis, 2016
Table 163: Product Profile – Aitan
Table 164: Efficacy of Aitan in Pretreated Nonsquamous NSCLC
Table 165: Aitan SWOT Analysis, 2016
Table 166: Product Profile – Fruquintinib
Table 167: Baseline Demographics in the Phase I Trial (HMP, NCT01645215) of Fruquintinib
Table 168: Efficacy of Fruquintinib in Advanced Solid Tumors
Table 169: Safety of Fruquintinib in Advanced Solid Tumors
Table 170: Fruquintinib SWOT Analysis, 2016
Table 171: Efficacy and Safety of ABP 215 in NSCLC in the Phase III Trial (NCT01966003)
Table 172: Product Profile – Abemaciclib
Table 173: Efficacy of Abemaciclib Monotherapy in Previously Treated NSCLC (NCT01394016)
Table 174: Efficacy of Abemaciclib in Combination with Other Therapies (NCT02079636)
Table 175: Safety of Abemaciclib in Combination with Multiple Single Agents
Table 176: Abemaciclib SWOT Analysis, 2016
Table 177: Product Profile – Tafinlar + Mekinist
Table 178: Demographics in Cohort B of the Pivotal Phase II BRF113928 Trial (GSK, NCT01336634)
Table 179: Efficacy of Tafinlar + Mekinist in Previously Treated BRAF V600E+ NSCLC
Table 180: Safety of Tafinlar + Mekinist in Previously Treated BRAF V600E+ NSCLC
Table 181: Tafinlar + Mekinist SWOT Analysis, 2016
Table 182: Product Profile – Veliparib
Table 183: Demographics in the Phase II NCT01560104 Trial
Table 184: Efficacy of VCP in Advanced NSCLC (NCT01560104)
Table 185: Efficacy of VCP by Smoking Status (NCT01560104)
Table 186: Safety of VCP in Advanced NSCLC (NCT01560104)
Table 187: Veliparib SWOT Analysis, 2016
Table 188: Product Profile – Seribantumab (MM-121)
Table 189: Demographics in Group A of the Phase I/II Trial (NCT00994123) of MM-121 + Tarceva in
Table 190: Efficacy of MM-121 + Tarceva in EGFR Wild-Type NSCLC
Table 191: Safety of MM-121 + Tarceva in EGFR Wild-Type NSCLC
Table 192: MM-121 SWOT Analysis, 2016
Table 193: Product Profile – Sacituzumab govitecan (IMMU-132)
Table 194: Demographics in the Phase II Portion of the Phase I/II Trial (NCT01631552)
Table 195: Efficacy of IMMU-132 in Pretreated NSCLC in the Phase I/II Trial (NCT01631552)
Table 196: Efficacy of IMMU-132 in Patients Who Progressed on Prior Checkpoint Inhibitor
Table 197: Safety of IMMU-132 in Pretreated NSCLC in the Phase I/II Trial (NCT01631552)
Table 198: IMMU-132 SWOT Analysis, 2016
Table 199: Product Profile – Plinabulin
Table 200: Efficacy of Plinabulin + Docetaxel in the Phase I/II Trial (NCT00630110)
Table 201: Safety of Plinabulin + Docetaxel in the Phase I/II Trial (NCT00630110)
Table 202: Plinabulin SWOT Analysis, 2016
Table 203: Early-Stage Clinical Development in NSCLC
Table 204: MET Status in the Phase II (NCT01610336) Trial
Table 205: Efficacy of Capmatinib + Iressa in MET+ NSCLC
Table 206: Demographics in the Phase II LURET Study
Table 207: Efficacy of Caprelsa in RET+ NSCLC
Table 208: Demographics in the Stage I of the Phase II NCT01639508 Trial
Table 209: Efficacy of Cometriq in RET+ NSCLC
Table 210: Key Events Impacting Sales for NSCLC in China, 2016
Table 211: NSCLC –Drivers and Barriers in urban China, 2015-2025
Table 212: Key Launch Dates – Part I
Table 213: Key Launch Dates – Part II
Table 214: Key Patent Expiries
Table 215 Average Body Weight and Surface Area Across the 8MM
Table 216: Average Cost of Therapy of Alimta in the 8MM
Table 217: Average Cost of Therapy of Alecensa in the 8MM
Table 218: Average Cost of Therapy of Avastin
Table 219: Average Cost of Therapy of Cyramza
Table 220: Average Cost of Therapy of Gilotrif
Table 221: Average Cost of Therapy of Iressa
Table 222: Average Cost of Therapy of Portrazza
Table 223: Average Cost of Therapy of Tagrisso
Table 224: Average Cost of Therapy of Tarceva
Table 225: Average Cost of Therapy of Vargatef
Table 226: Average Cost of Therapy of Xalkori
Table 227: Average Cost of Therapy of Zykadia
Table 228: Average Cost of Therapy of Keytruda
Table 229: Average Cost of Therapy of Opdivo
Table 230: Average Cost of Therapy of Tecentriq
Table 231: Average Cost of Therapy of Conmana
Table 232: High-Prescribing Physicians Surveyed by Country